MedTrace Logo

Sleep Apnea in Sickle Cell Disease

NCT03753854 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-12-28

No results posted yet for this study

Summary

Despite the fact that obstructive sleep apnoea (OSA) is highly prevalent in the sickle cell population, studies focusing on the associations of the two diseases and their common pathophysiological mechanisms are scarce. OSA is one of the most common conditions responsible for hemoglobin desaturation. The nocturnal hemoglobin desaturation occurring in some sickle cell disease (SCD) patients with OSA could trigger hemoglobin S polymerization and red blood cell (RBC) sickling, leading to further blood rheological alterations, hence increasing the risks for VOC. Moreover, OSA has been demonstrated to increase oxidative stress and inflammation in non Sickle Cell Disease (SCD) patients, which, in SCD patients, could increase the risk for complications. Finally, OSA is accompanied by impaired vascular function and autonomic nervous system dysfunction in the general population. Indeed, the presence of OSA in SCD could increase the clinical severity of patients and the frequency of VOC.

Conditions

Interventions

DIAGNOSTIC_TEST

polysomnography and oxygen saturation exam

Measurement of the Apnea/hypopnea index (AHI) and oxygen saturation

BIOLOGICAL

calculation of VOC frequency between the first polysomnography and the end of the first year of continuous positive airway pressure treatment

calculation of VOC rate within the two previous years or between first polysomnography and one year of continuous positive airway pressure treatment

BIOLOGICAL

Blood samples

Blood samples with measurements of hematological, hemorheological, inflammatory and blood coagulation markers

OTHER

Physiological measurements

Evaluation of microvascular reactivity and autonomic nervous system activity

OTHER

Continuous Positive Airway Pressure

Continuous Positive Airway Pressure during 1 year

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-28
Primary Completion
2021-11-29
Completion
2021-11-29

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03753854 on ClinicalTrials.gov